← Back to Analyst Consensus 
SHC Buy
Sotera Health Co
Current Price —
Implied Upside —
Analysts 15
30-Day Momentum
▲ 0 upgrades / ▼ 1 downgrades / 0 reiterations from 1 firms
Next Earnings
Nov 3, 2026 (8 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 14, 2026 | JP Morgan | downgrade | Neutral → Underweight | — | 54% |
| Aug 7, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Aug 7, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Aug 7, 2026 | Piper Sandler | reiterate | Overweight → Overweight | — | 54% |
| Aug 7, 2026 | JP Morgan | maintain | Neutral → Neutral | — | 54% |
| Jun 24, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Jun 5, 2026 | Goldman Sachs | initiate | Buy → Buy | — | 54% |
| May 6, 2026 | Piper Sandler | reiterate | Overweight → Overweight | — | 54% |
| Apr 14, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Feb 24, 2026 | Citigroup | maintain | Buy → Buy | $23 | 54% |
| Jan 9, 2026 | Piper Sandler | upgrade | Neutral → Overweight | $24 | 54% |
| Dec 18, 2025 | William Blair | initiate | — → Outperform | $0 | 48% |
| Nov 13, 2025 | BMO Capital | initiate | — → Outperform | $19 | 53% |
| Nov 5, 2025 | JP Morgan | maintain | Neutral → Neutral | $16 | 54% |
| Nov 5, 2025 | Barclays | maintain | Overweight → Overweight | $20 | 53% |
| Nov 5, 2025 | Piper Sandler | maintain | Neutral → Neutral | $17 | 54% |
| Oct 2, 2025 | Barclays | maintain | Overweight → Overweight | $19 | 53% |
| Jun 24, 2025 | Barclays | maintain | Overweight → Overweight | $13 | 53% |
| May 5, 2025 | Goldman Sachs | upgrade | Neutral → Buy | $17 | 54% |
| Apr 23, 2025 | Piper Sandler | maintain | Neutral → Neutral | $13 | 54% |
| Apr 10, 2025 | Barclays | maintain | Overweight → Overweight | $12 | 53% |
| Feb 28, 2025 | Barclays | maintain | Overweight → Overweight | $16 | 53% |
| Feb 18, 2025 | Barclays | maintain | Overweight → Overweight | $17 | 53% |
| Nov 21, 2024 | RBC Capital | reiterate | Outperform → Outperform | $17 | 55% |
| Nov 6, 2024 | Citigroup | maintain | Buy → Buy | $20 | 54% |
| Aug 6, 2024 | Barclays | maintain | Overweight → Overweight | $17 | 53% |
| Aug 6, 2024 | RBC Capital | reiterate | Outperform → Outperform | $17 | 55% |
| May 21, 2024 | Piper Sandler | initiate | — → Neutral | $13 | 54% |
| Apr 10, 2024 | Barclays | maintain | Overweight → Overweight | $14 | 53% |
| Apr 3, 2024 | Citigroup | upgrade | Neutral → Buy | $16 | 54% |
| Mar 25, 2024 | Jefferies | upgrade | Hold → Buy | $15.5 | 52% |
| Mar 11, 2024 | RBC Capital | reiterate | Outperform → Outperform | $20 | 55% |
| Mar 4, 2024 | RBC Capital | reiterate | Outperform → Outperform | $20 | 55% |
| Feb 28, 2024 | Barclays | maintain | Overweight → Overweight | $19 | 53% |
| Feb 6, 2024 | Keybanc | initiate | — → Sector Weight | $0 | 53% |
| Jan 25, 2024 | Barclays | maintain | Overweight → Overweight | $17 | 53% |
| Nov 2, 2023 | RBC Capital | maintain | Outperform → Outperform | $20 | 55% |
| Nov 2, 2023 | Barclays | maintain | Overweight → Overweight | $15 | 53% |
| Aug 4, 2023 | RBC Capital | maintain | Outperform → Outperform | $22 | 55% |
| Aug 4, 2023 | Keybanc | maintain | Overweight → Overweight | $23 | 53% |
| Jun 26, 2023 | Keybanc | upgrade | Sector Weight → Overweight | $24 | 53% |
| Jun 22, 2023 | Keybanc | maintain | — → Sector Weight | $0 | 53% |
| May 4, 2023 | RBC Capital | maintain | — → Outperform | $18 | 55% |
| May 4, 2023 | Barclays | maintain | — → Overweight | $20 | 53% |
| Apr 4, 2023 | Barclays | maintain | — → Overweight | $21 | 53% |
| Mar 1, 2023 | RBC Capital | maintain | — → Outperform | $19 | 55% |
| Jan 23, 2023 | JP Morgan | upgrade | Underweight → Neutral | $18 | 54% |
| Jan 11, 2023 | Barclays | upgrade | Underweight → Overweight | $22 | 53% |
| Jan 11, 2023 | Wolfe Research | upgrade | Peer Perform → Outperform | $25 | 53% |
| Nov 23, 2022 | Goldman Sachs | maintain | — → Neutral | $8 | 54% |
Price Target Trend
May 27, 2026 Oct 26, 2026
EPS Estimates
0q —
0y —
+1y —
+1q —
Cross-Platform Signals
No cross-platform signals in the last 90 days